Medtronic (NYSE: MDT), the US-Irish medical technology giant, has announced that it has received approvals from Chinese regulatory authorities for its innovative heart pulse electric field ablation device and disposable heart pulse electric field ablation catheter. These products, when used in tandem, employ the non-thermal effects of pulsed electric fields to address drug-resistant, recurrent, and symptomatic forms of paroxysmal atrial fibrillation, as well as drug-resistant, recurrent, and symptomatic persistent atrial fibrillation with a duration of less than one year.
The technology stands out in the medical device landscape due to its ability to selectively target and destroy myocardial tissue, thus avoiding the risks of collateral tissue damage associated with temperature transfer that can occur with traditional radiofrequency ablation and cryoablation methods. This advancement is expected to offer patients and medical professionals an improved treatment option for managing atrial fibrillation. – Flcube.com
